159 related articles for article (PubMed ID: 31175991)
1. Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form.
Ronchi F; Sereno A; Paide M; Sacré P; Guillaume G; Stéphenne V; Goole J; Amighi K
Int J Pharm; 2019 Aug; 567():118416. PubMed ID: 31175991
[TBL] [Abstract][Full Text] [Related]
2. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
3. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
Chuong MC; Taglieri CA; Kerr SG
Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339
[TBL] [Abstract][Full Text] [Related]
4. Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters.
Riekes MK; Dereymaker A; Berben P; Augustijns P; Stulzer HK; Van den Mooter G
Int J Pharm; 2017 Mar; 520(1-2):49-58. PubMed ID: 28153650
[TBL] [Abstract][Full Text] [Related]
5. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
[TBL] [Abstract][Full Text] [Related]
6. Dissolution of omeprazole from delayed-release solid oral dosage forms.
Farinha A; Bica A; Martins JM; Pais JP
Drug Dev Ind Pharm; 2000 Jul; 26(7):785-90. PubMed ID: 10872100
[TBL] [Abstract][Full Text] [Related]
7. Achieving gastroresistance without coating: Formulation of capsule shells from enteric polymers.
Barbosa JAC; Al-Kauraishi MM; Smith AM; Conway BR; Merchant HA
Eur J Pharm Biopharm; 2019 Nov; 144():174-179. PubMed ID: 31541663
[TBL] [Abstract][Full Text] [Related]
8. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
Kołodziejczyk MK; Kołodziejska J; Zgoda MM
Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
[TBL] [Abstract][Full Text] [Related]
9. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD).
Leopold CS; Eikeler D
J Drug Target; 1998; 6(2):85-94. PubMed ID: 9886233
[TBL] [Abstract][Full Text] [Related]
10. Stability of omeprazole in an extemporaneously prepared oral liquid.
Quercia RA; Fan C; Liu X; Chow MS
Am J Health Syst Pharm; 1997 Aug; 54(16):1833-6. PubMed ID: 9269520
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease.
Patel MM; Amin AF
Pharm Dev Technol; 2013; 18(2):390-400. PubMed ID: 22304735
[TBL] [Abstract][Full Text] [Related]
12. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers.
Stroyer A; McGinity JW; Leopold CS
J Pharm Sci; 2006 Jun; 95(6):1342-53. PubMed ID: 16625655
[TBL] [Abstract][Full Text] [Related]
13. Extended release delivery system of metoprolol succinate using hot-melt extrusion: effect of release modifier on methacrylic acid copolymer.
Sawant KP; Fule R; Maniruzzaman M; Amin PD
Drug Deliv Transl Res; 2018 Dec; 8(6):1679-1693. PubMed ID: 29948916
[TBL] [Abstract][Full Text] [Related]
14. Influence of lidocaine forms (salt vs. freebase) on properties of drug-eudragit® L100-55 extrudates prepared by reactive melt extrusion.
Liu X; Ma X; Kun E; Guo X; Yu Z; Zhang F
Int J Pharm; 2018 Aug; 547(1-2):291-302. PubMed ID: 29883791
[TBL] [Abstract][Full Text] [Related]
15. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
16. Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole.
He W; Fan LF; Du Q; Xiang B; Li CL; Bai M; Chang YZ; Cao DY
Chem Pharm Bull (Tokyo); 2009 Feb; 57(2):122-8. PubMed ID: 19182399
[TBL] [Abstract][Full Text] [Related]
17. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.
Burnett JE; Balkin ER
Am J Health Syst Pharm; 2006 Nov; 63(22):2240-7. PubMed ID: 17090745
[TBL] [Abstract][Full Text] [Related]
18. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
[TBL] [Abstract][Full Text] [Related]
19. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery.
Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M
Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
Sharma VK
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
